CD19 and cancer: This study showed that allogeneic CAR-NK cells targeting CD19 were well-tolerated and effective in patients with relapsed or refractory CD19-positive cancers, highlighting the potential of CAR-NK as an alternative immunotherapy approach (52, 77).